Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer
Authors
Hiroyuki Konno
Megumi Baba
Tuyoshi Shoji
Manabu Ohta
Shohati Suzuki
Satoshi Nakamura
Publication date
01-10-2002
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 6/2002
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1020392309715

Other articles of this Issue 6/2002

Clinical & Experimental Metastasis 6/2002 Go to the issue

OriginalPaper

Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells

OriginalPaper

Investigations into the potential role of aberrant N-acetylgalactosamine glycans in tumour cell interactions with basement membrane components

OriginalPaper

Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11

OriginalPaper

Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model

OriginalPaper

Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma

OriginalPaper

Flow cytometry correlates with RT-PCR for detection of spiked but not circulating colorectal cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits